A. Kashishian

发表

Discovery of Potent and Selective MTH1 Inhibitors for Oncology: Enabling Rapid Target (In)Validation.

S. Viatchenko‐Karpinski, J. Sudhamsu, Xiaowu Chen, 2019, ACS medicinal chemistry letters.

In vivo binding properties of SH2 domains from GTPase-activating protein and phosphatidylinositol 3-kinase

Jonathan A. Cooper, A. Kashishian, 1993 .

GTPase-activating protein and phosphatidylinositol 3-kinase bind to distinct regions of the platelet-derived growth factor receptor beta subunit

A. Kazlauskas, A. Kashishian, M. Valius, 1992 .

CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability.

R. Ulrich, J. Byrd, A. Johnson, 2011, Blood.

Two signaling molecules share a phosphotyrosine-containing binding site in the platelet-derived growth factor receptor

Jonathan A. Cooper, J. Schlessinger, A. Mondino, 1993, Molecular and cellular biology.

p110δ, a Novel Phosphatidylinositol 3-Kinase Catalytic Subunit That Associates with p85 and Is Expressed Predominantly in Leukocytes*

Jonathan A. Cooper, M. Hoekstra, A. Vojtek, 1997, The Journal of Biological Chemistry.

Direct Measurement of the Intracellular Concentration of 8-Oxo-2'-Deoxyguanosine-5'-Triphosphate by LC-MS/MS

K. Schwartz, A. Ray, Ting Wang, 2020 .

toDistinct Regions ofthePlatelet-Derived GrowthFactor Receptor 1BSubunit

Jonathan A. Cooper, A. Kazlauskas, A. Kashishian, 1992 .

Phosphorylation Sites at the C-terminus of the Platelet-Derived Growth Factor Receptor Bind Phospholipase Cyl

Jonathan A. Cooper, A. Kashishian, 2022 .

Phosphorylation sites at the C-terminus of the platelet-derived growth factor receptor bind phospholipase C gamma 1.

J. Cooper, A. Kashishian, 1993, Molecular biology of the cell.

PI3Kδ inhibitor, GS-1101 (CAL-101), attenuates pathway signaling, induces apoptosis, and overcomes signals from the microenvironment in cellular models of Hodgkin lymphoma.

V. Diehl, A. Younes, L. Miller, 2012, Blood.

CAL-101 (GS-1101), a Specific Inhibitor of Phosphatidylinositol-3-Kinase-Delta (PI3Kδ), Disrupts Signals From the Microenvironment, Induces Apoptosis, and Enhances the Antitumor Activity of Everolimus (RAD001), An Inhibitor of Mammalian Target of Rapamycin (mTOR), in Mantle Cell Lymphoma (MCL),

David W. Johnson, R. Ulrich, L. Miller, 2011 .

CAL-101, a Potent Selective Inhibitor of the p110δ Isoform of Phosphatidylinositol 3-kinase, Attenuates Pathway Signaling, Induces Apoptosis, and Overcomes Signals From the Microenvironment In Cellular Models of Hodgkin Lymphoma

V. Diehl, A. Kashishian, B. Lannutti, 2010 .

DNA-dependent protein kinase is a molecular target for the development of noncytotoxic radiation-sensitizing drugs.

D. Hallahan, Heidi Chen, L. Geng, 2005, Cancer research.

DNA-Dependent Protein Kinase Is a Molecular Target for the Development of Noncytotoxic Radiation–Sensitizing Drugs

D. Hallahan, Heidi Chen, L. Geng, 2005 .

Discovery of a Phosphoinositide 3-Kinase (PI3K) β/δ Inhibitor for the Treatment of Phosphatase and Tensin Homolog (PTEN) Deficient Tumors: Building PI3Kβ Potency in a PI3Kδ-Selective Template by Targeting Nonconserved Asp856.

J. Chandrasekhar, M. Mcgrath, G. Phillips, 2017, Journal of medicinal chemistry.

Discovery of Orally Efficacious Phosphoinositide 3-Kinase δ Inhibitors with Improved Metabolic Stability.

J. Chandrasekhar, J. R. Somoza, M. Mcgrath, 2016, Journal of medicinal chemistry.

A new function for a phosphotyrosine phosphatase: linking GRB2-Sos to a receptor tyrosine kinase

Jonathan A. Cooper, J. Schlessinger, A. Batzer, 1994, Molecular and cellular biology.

Targeting nonclassical oncogenes for therapy in T-ALL.

A. Ferrando, C. Cordon-Cardo, Dosh Whye, 2012, Cancer cell.

Activation of the SH2-containing phosphotyrosine phosphatase SH-PTP2 by its binding site, phosphotyrosine 1009, on the human platelet-derived growth factor receptor.

C. Walsh, B. Neel, S. Shoelson, 1993, The Journal of biological chemistry.

In vivo binding properties of SH2 domains from GTPase-activating protein and phosphatidylinositol 3-kinase

Jonathan A. Cooper, A. Kashishian, 1993, Molecular and cellular biology.

Phosphorylation sites in the PDGF receptor with different specificities for binding GAP and PI3 kinase in vivo.

Jonathan A. Cooper, A. Kazlauskas, A. Kashishian, 1992, The EMBO journal.

Effects of Isoform-selective Phosphatidylinositol 3-Kinase Inhibitors on Osteoclasts

S. Dixon, S. Sims, F. Jirik, 2013, The Journal of Biological Chemistry.

1 Effects of Isoform-Selective Phosphatidylinositol 3-Kinase Inhibitors on Osteoclasts : ACTIONS ON CYTOSKELETAL ORGANIZATION , SURVIVAL AND RESORPTION * S

S. Dixon, S. Sims, F. Jirik, 2013 .

DNA-dependent protein kinase inhibitors as drug candidates for the treatment of cancer.

J. Schiro, A. Kashishian, J. Halbrook, 2003, Molecular cancer therapeutics.

AKAP79 Inhibits Calcineurin through a Site Distinct from the Immunophilin-binding Region*

M. Hoekstra, Monique Howard, C. Loh, 1998, The Journal of Biological Chemistry.

GTPase-activating protein and phosphatidylinositol 3-kinase bind to distinct regions of the platelet-derived growth factor receptor beta subunit

Jonathan A. Cooper, A. Kazlauskas, J. Cooper, 1992, Molecular and cellular biology.

PI3Kδ Inhibitor Idelalisib Inhibits AKT Signaling In Myelofibrosis Patients On Chronic JAK Inhibitor Therapy

C. Quéva, J. Gotlib, S. Coutre, 2013 .

Targeting nonclassical oncogenes for therapy in T-ALL.

A. Ferrando, C. Cordon-Cardo, Dosh Whye, 2012, Cancer cell.